GSK
GSK
901 hedge funds and large institutions have $15.7B invested in GSK in 2022 Q2 according to their latest regulatory filings, with 104 funds opening new positions, 349 increasing their positions, 267 reducing their positions, and 128 closing their positions.
83% more call options, than puts
Call options by funds: $459M | Put options by funds: $251M
32% more capital inflows, than outflows
Capital inflows: $2.28B | Capital outflows: $1.73B
31% more repeat investments, than reductions
Existing positions increased: 349 | Existing positions reduced: 267
0.36% more ownership
Funds ownership: 13.03% → 13.39% (+0.36%)
0% more funds holding in top 10
Funds holding in top 10: 17 → 17 (0)
3% less funds holding
Funds holding: 930 → 901 (-29)
19% less first-time investments, than exits
New positions opened: 104 | Existing positions closed: 128
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Parallax Volatility Advisers
San Francisco,
California
|
+$708M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$324M |
| 3 |
Morgan Stanley
New York
|
+$158M |
| 4 |
Bain Capital Public Equity Management II
Boston,
Massachusetts
|
+$95.6M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$81.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dodge & Cox
San Francisco,
California
|
-$508M |
| 2 |
Black Creek Investment Management
Toronto,
Ontario, Canada
|
-$401M |
| 3 |
Hotchkis & Wiley Capital Management
Los Angeles,
California
|
-$164M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$79.5M |
| 5 |
HighTower Advisors
Chicago,
Illinois
|
-$57.1M |
GSK Hedge Fund Activity: Q2 2022 in Review
901 of the 5,963 institutional investors tracked by Wall St. Rank reported a position in GSK (GSK) for Q2 2022, worth a combined $15.7B — up 8.4% from $14.4B a quarter earlier.
Sellers outnumbered buyers: 128 funds closed out of GSK and 104 opened new positions — a net loss of 24 holders — while 267 trimmed existing stakes and 349 added.
The largest buyer was Parallax Volatility Advisers, opening a new position worth an estimated $708M. The largest seller was Dodge & Cox, cutting an estimated $508M.
- 901 institutional investors held GSK (GSK) as of Q2 2022, down from 930 in Q1 2022.
- Funds reported $15.7B of GSK stock for Q2 2022, up 8.4% quarter-over-quarter.
- 104 funds opened new GSK positions in Q2 2022 and 128 closed out, a net change of -24 holders.
- The largest GSK buyer in Q2 2022 was Parallax Volatility Advisers, an estimated $708M added.
- The largest GSK seller in Q2 2022 was Dodge & Cox, an estimated $508M sold.
Based on aggregated 13F filings for Q2 2022.